Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-NOTA-PRGD2 PET/CT in Lung Injury and Pulmonary Fibrosis
NCT02511197Phase 1Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- May 2015
- Primary completion
- Dec 2017
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 68Ga-BNOTA-PRGD2 in not applicable; "lung injury" is not a specific disease and pulmonary fibrosis (PF), sponsored by Peking Union Medical College Hospital. Primary endpoints: Visual assessment of lung lesions at 1 year and Semiquantitative assessment of lung lesions at 1 year. Status: unknown.
02
Drugs
68Ga-BNOTA-PRGD2
03
Conditions
not applicable; "lung injury" is not a specific diseasepulmonary fibrosis (PF)
Beyond the preview
Go deeper on NCT02511197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02511197.